Menu
Annual · values202520242023202220212020201920182017
Operating Cash Flow-16.34 M USD-68.92 M USD-125.18 M USD-124.82 M USD-71.93 M USD-38.31 M USD-29.53 M USD-19.94 M USD-20.82 M USD
Depreciation & Amortization9.53 M USD14.02 M USD13.71 M USD9.62 M USD3.35 M USD1.48 M USD1.13 M USD1.32 M USD1.50 M USD
Stock-Based Compensation4.53 M USD9.74 M USD15.18 M USD22.42 M USD9.72 M USD1.55 M USD1.35 M USD1.19 M USD382830 USD
Capital Expenditures0 USD61056 USD331716 USD1.02 M USD
Cash Flow from Investing-12.75 M USD73.84 M USD24.16 M USD82.77 M USD-278.06 M USD-2.45 M USD-61056 USD-331716 USD-1.02 M USD
Cash Flow from Financing24.04 M USD-13.69 M USD113.81 M USD23.01 M USD336.11 M USD61.90 M USD30.38 M USD35.78 M USD17.61 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-38.31 M USD-29.59 M USD-20.28 M USD-21.84 M USD

Bionano Genomics develops genome analysis software that enables genomics laboratories to analyze and interpret genomic data across multiple platforms, generating comprehensive insights for research and clinical applications. The company's solutions are designed to detect genomic variations and provide a unified view of genome data, addressing critical questions in cancer diagnosis, genetic disease detection, and treatment planning. Bionano Genomics serves the genomics and clinical laboratory markets, offering tools that integrate data from various sequencing and analysis technologies. The company operates in the life sciences and healthcare technology sector, where it plays a role in advancing precision medicine and improving diagnostic capabilities for healthcare providers and research institutions worldwide.